Mirum Pharmaceuticals, Inc.
MIRMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Valued at $7.25B, MIRM is a mid-cap name in its sector. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Market Cap
$7.25B
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
-632.23
EPS (TTM)
$-13.75
EPS (Fwd)
$-0.19
ROE
-335.8%
ROA
-5.9%
Cash
$386.3M
Total Debt
$323.8M
Free CF
$166.9M
52W Change
128.9%
Annual Financials
Cash vs Debt
With $386.3M in cash and $323.8M in debt, MIRM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $166.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -335.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $77.1M (2022) to $521.3M (2025), reflecting a 576% increase over the period.
MIRM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing MIRM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.